Literature DB >> 11069469

Imiquimod: a novel treatment for lentigo maligna.

I Ahmed1, J Berth-Jones.   

Abstract

Lentigo maligna is the in situ phase of lentigo maligna melanoma, and if left untreated it may progress to invasive melanoma. It most commonly occurs on the exposed sites of the face and neck of middle-aged or elderly patients. Conventional surgery using a 5-10 mm margin is the recommended treatment; however, lesions can be quite large and surgical removal may involve extensive plastic repair. We report an elderly patient with a large lentigo maligna on the scalp who was reluctant to have surgery. We tried topical imiquimod 5% cream (Aldara), a local immunomodulator, which has recently become available for the treatment of external genital and perianal warts. Initially used over a test area and then over the whole of the lesion, for a total of 7 months, the imiquimod cream resulted in complete clinical and histological cure. The patient has been followed up for 9 months without evidence of recurrence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069469     DOI: 10.1046/j.1365-2133.2000.03787.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  16 in total

1.  Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.

Authors:  Tomoko Hayashi; Michael Chan; John T Norton; Christina C N Wu; Shiyin Yao; Howard B Cottam; Rommel I Tawatao; Maripat Corr; Dennis A Carson; Gregory A Daniels
Journal:  Melanoma Res       Date:  2011-02       Impact factor: 3.599

Review 2.  The role of topical immune response modifiers in skin cancer.

Authors:  Courtney Woodmansee; Jessica Pillow; Robert B Skinner
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil.

Authors:  Valerie Florin; Eve Desmedt; Sophie Vercambre-Darras; Laurent Mortier
Journal:  Invest New Drugs       Date:  2011-07-13       Impact factor: 3.850

4.  Toll-like receptors and cutaneous melanoma.

Authors:  Ilaria Coati; Serena Miotto; Irene Zanetti; Mauro Alaibac
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

5.  Topical Imiquimod Treatment of Lentigo Maligna.

Authors:  F Ventura; J Rocha; J C Fernandes; F Pardal; C Brito
Journal:  Case Rep Dermatol       Date:  2009-10-31

6.  Melanoma in Situ Treated with Topical Imiquimod for Management of Persistently Positive Margins: A Review of Treatment Methods.

Authors:  Qing Fan; Stephanie Cohen; Becky John; Adam I Riker
Journal:  Ochsner J       Date:  2015

Review 7.  Current and emerging technologies in melanoma diagnosis: the state of the art.

Authors:  Estee L Psaty; Allan C Halpern
Journal:  Clin Dermatol       Date:  2009 Jan-Feb       Impact factor: 3.541

Review 8.  [Precancerous and early invasive carcinomas: non-surgical treatment of head and facial skin].

Authors:  E Haneke
Journal:  HNO       Date:  2009-04       Impact factor: 1.284

9.  [Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases].

Authors:  C Loquai; D Nashan; D Metze; U Beiteke; K W Rüping; T A Luger; S Grabbe
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

10.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.